Europe Pain Management Devices Market 2021-2031

Europe pain management devices was valued at $1,084.9 million in 2021 and will grow by 8.0% annually over 2021-2031, driven by the growing demand for chronic pain management among the geriatric population, the increasing availability of technically advanced pain management devices, supportive reimbursement policies and adverse effects of pain medications, and the growing awareness of pain management devices. Highlighted with 33 tables and 47 figures, this 100-page report “Europe Pain Management Devices Market 2021-2031 by Product (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps, Ablation Devices), Application (Neuropathic Pain, Musculoskeletal Pain, Cancer Pain, Facial & Migraine Pain, Others), Mode of Purchase (Prescription, OTC), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pain management devices market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe pain management devices market in every aspect of the classification from perspectives of Product, Application, Mode of Purchase, and Country. Based on Product, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Neuromodulation & Neurostimulation Devices o Spinal Cord Stimulators o Transcutaneous Electrical Nerve Stimulation (TENS) Devices o Sacral Nerve Stimulators o Deep Brain Stimulators o Other Neuromodulation & Neurostimulation Devices • Analgesic Infusion Pumps o External Infusion Pumps o Intrathecal Infusion Pumps • Ablation Devices o Radiofrequency Ablation Devices o Cryoablation Devices Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Neuropathic Pain • Musculoskeletal Pain • Cancer Pain • Facial & Migraine Pain • Other Applications By Mode of Purchase, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Prescription • Over-the-counter (OTC) Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Netherlands • Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Application and Mode of Purchase over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Abbott Laboratories B. Braun Melsungen AG Baxter International Inc. Becton, Dickinson and Company Boston Scientific Corp. Colfax Corporation (DJO Global LLC) Johnson & Johnson (Codman and Shurtleff, Inc.) Kimberly Clark Corporation Medtronic Plc. Nevro Corp Pfizer, Inc. Smiths Medical, Inc. Stryker Corp. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)